Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

417
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
417
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

407
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
407
Equivalence: In Vitro and In Vivo Bioequivalence01:17

Equivalence: In Vitro and In Vivo Bioequivalence

387
Bioequivalence studies are crucial in evaluating whether new drugs can match an approved one regarding pharmacological effects and clinical performance. These studies test if drugs, despite different dosage forms, share identical plasma concentration-time profiles. Three types of equivalence are central to these studies: chemical, pharmaceutical, and therapeutic. Chemical equivalence indicates that two or more drug products contain identical active ingredients in equal amounts. Pharmaceutical...
387
Bioequivalence studies: Biowaivers01:13

Bioequivalence studies: Biowaivers

430
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
430
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

354
The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
354
Bioequivalence: Overview01:16

Bioequivalence: Overview

2.2K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
2.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Conformational dynamics of CRISPR-Cas type I-F-HNH inform nickase engineering in a cascade scaffold.

Nucleic acids research·2026
Same author

Evaluation of Incurred Subject Period Re-analysis (ISPR) as a Tool to Distinguish Fraudulent Pharmacokinetic Profile Pairs from Non-fraudulent Pairs.

The AAPS journal·2024
Same author

Conformational landscape of the type V-K CRISPR-associated transposon integration assembly.

Molecular cell·2024
Same author

Retron-Eco1 assembles NAD<sup>+</sup>-hydrolyzing filaments that provide immunity against bacteriophages.

Molecular cell·2024
Same author

Structure of the TnsB transposase-DNA complex of type V-K CRISPR-associated transposon.

Nature communications·2022
Same author

Increased Patient's Risk Associated with the Canadian Bioequivalence Guidance Due to Outlier Removal.

Therapeutic innovation & regulatory science·2021

Related Experiment Video

Updated: Apr 28, 2026

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

839

A sequential bioequivalence design with a potential ethical advantage.

Anders Fuglsang1

  • 1Fuglsang Pharma, Hiort Lorenzens Vej 6C, 6100, Haderslev, Denmark, a.fuglsang@ymail.com.

The AAPS Journal
|May 30, 2014
PubMed
Summary
This summary is machine-generated.

This study presents a novel two-stage bioequivalence testing method. It offers advantages in sample size and controls statistical errors, making it an ethical and economic alternative for drug development.

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models
02:44

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models

Published on: July 26, 2024

3.1K

Related Experiment Videos

Last Updated: Apr 28, 2026

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow
08:58

Efficient Sampling of Genetically Encoded Biosensor Design Space Enabled with a Design of Experiments and Automation Workflow

Published on: October 17, 2025

839
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.0K
Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models
02:44

Use of Micropipette-Guided Drug Administration as an Alternative Method to Oral Gavage in Rodent Models

Published on: July 26, 2024

3.1K

Area of Science:

  • Pharmacokinetics and Drug Development
  • Biostatistics
  • Regulatory Science

Background:

  • Bioequivalence studies are crucial for generic drug approval.
  • Existing methods, like Potvin's, may require large sample sizes or have limitations.
  • Optimizing sample size while maintaining statistical rigor is essential.

Purpose of the Study:

  • To introduce and evaluate a novel two-stage approach for bioequivalence assessment.
  • To compare the proposed method with existing approaches, particularly Potvin's designs.
  • To assess the method's performance regarding sample size, type I error, and statistical power.

Main Methods:

  • A two-stage mandatory design for bioequivalence evaluation.
  • Derivation from Potvin's method C.
  • Incorporation of a futility rule based on stage 2 sample size.

Main Results:

  • The proposed method demonstrates advantages in sample size, especially with high variability and low initial sample sizes.
  • Type I error rates are controlled at or below 5%, with minimal power trade-offs.
  • Average total sample sizes are largely independent of the initial sample size.
  • Incorporating a futility rule can lead to improved power or reduced sample size compared to prior methods.

Conclusions:

  • The new two-stage bioequivalence method is a potentially attractive, ethical, and economical alternative to existing designs.
  • It offers efficient sample size management while ensuring statistical validity.
  • The futility rule enhances the method's practical applicability and efficiency.